Adaptimmune Therapeutics PLC reports results for the quarter ended in December - Earnings Summary

Adaptimmune Therapeutics

14/03/2022 13:31

* Adaptimmune Therapeutics PLC  ADAP.OQ  reported a
quarterly
adjusted loss of 4 cents​​ per share for the quarter ended in
December. The mean expectation of seven analysts for the quarter
was for earnings of 14 cents per share.
    * Revenue fell 5.7% to $1.42 million from a year ago; 
analysts
expected $96.45 million. 
    * Adaptimmune Therapeutics PLC's reported EPS for the
quarter was
a loss of 4 cents​.
    * The mean earnings estimate of analysts had risen by
about 333.3%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Adaptimmune Therapeutics PLC shares had fallen by 51.5%
this
quarter.
    * The company reported a quarterly loss of $38.86 million.
    * Wall Street's median 12-month price target for Adaptimmune
Therapeutics PLC is $9.00 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and 1 "sell" or "strong sell." 

This summary was machine generated March 14 at 01:30 p.m.  ​All
figures in US dollars unless otherwise stated